Founded Year

2018

Stage

IPO | IPO

Total Raised

$20.06M

Date of IPO

11/8/2021

Market Cap

96.85B

About GENINUS

GENINUS is a genetic testing company that aims to commercialize technologies that analyze various genetic information. The company is developing a health management service based on individuals' genetic information, applying an artificial intelligence learning algorithm to improve the accuracy of diagnosis and testing.

GENINUS Headquarter Location

15F, Room 1514-1515 7, Beobwon-ro 11-gil, Songpa-gu

Seoul, 05836,

South Korea

+82 02-2148-6577

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

GENINUS's Products & Differentiation

See GENINUS's products and how their products differentiate from alternatives and competitors

  • Celinus

    Celinus™ is a single cell RNA sequencing service. It allows the direct measurement of gene expression and genetic alteration at scale with single cell resolution to quantify intracellular heterogeneity and characterize cell types, states, and cellular transition dynamics. The service includes support for Single Cell Gene Expression, Single Cell Immune Profiling, Single Nucleus Gene Expression, Single Cell Multiome ATAC, and Spatial Gene Expression (Visium).

    Differentiation

    Due to long experience and experts, GENINUS has highest level proficiency and accuracy in single cell analysis in Asia pacific region. 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing GENINUS

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GENINUS is included in 6 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

M

Medical Devices

8,448 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,900 items

GENINUS Patents

GENINUS has filed 2 patents.

The 3 most popular patent topics include:

  • Antineoplastic drugs
  • Bioinformatics
  • Cancer treatments
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/2/2019

Experimental cancer drugs, Tyrosine kinase receptors, Clusters of differentiation, Cancer treatments, Antineoplastic drugs

Application

Application Date

12/2/2019

Grant Date

Title

Related Topics

Experimental cancer drugs, Tyrosine kinase receptors, Clusters of differentiation, Cancer treatments, Antineoplastic drugs

Status

Application

Latest GENINUS News

Geninus endures rocky start in Korean Stock Exchange debut, but raises $34M

Nov 9, 2021

Nov. 8, 2021 Geninus Inc. endured a difficult debut on Korea Exchange’s Kosdaq board, but still raised ?40 billion (US$33.83 million) through its listing. The 2 million shares on offer tumbled 25.56% at ?13,400 (US$11.33) at the close of trading on Nov. 8, after Geninus priced them at ?20,000.

GENINUS Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GENINUS Rank

  • When was GENINUS founded?

    GENINUS was founded in 2018.

  • Where is GENINUS's headquarters?

    GENINUS's headquarters is located at 15F, Room 1514-1515, Seoul.

  • What is GENINUS's latest funding round?

    GENINUS's latest funding round is IPO.

  • How much did GENINUS raise?

    GENINUS raised a total of $20.06M.

  • Who are the investors of GENINUS?

    Investors of GENINUS include IMM Investment, Korea Investment Partners, Company K Partners, KB Investment, DAOL Investment and 5 more.

  • Who are GENINUS's competitors?

    Competitors of GENINUS include Foundation Medicine.

  • What products does GENINUS offer?

    GENINUS's products include Celinus and 2 more.

You May Also Like

A
ADNAvance Technologies

Adnavance Technologies Inc is developing enabling technology applications that use the conductivity properties of both normal and novel metallic forms of DNA aimed at large biosensormolecular diagnostics and energy generationmanagement markets

Perthera Logo
Perthera

Perthera uses AI to analyze patient medical and molecular data to enable hospitals, physicians & advocacy groups to deliver personalized cancer care. The Perthera Platform matches patients to ranked therapeutic options to improve their clinical outcomes and allows patient data access to the key segments in the Precision Oncology market. It was founded in 2012 and is based in McLean, Virginia.

Lifebit Logo
Lifebit

Lifebit builds a cloud-based, cognitive system that can reason about DNA data like humans do. It aims to allow wider access to global biomedical data for drug discovery through the development of its clinico-genomic database.Per the company, it has a patented technology for federating genomic data in a way that allows researchers to get more insights while keeping the data secure.

P
Prognomix

Predict to Prevent  Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development  of  presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention

Cofactor Genomics Logo
Cofactor Genomics

Cofactor Genomics bridges the precision medicine gap by building diagnostic tools to match the right patient to the right treatment at the right time. Cofactor provides Predictive Immune Modeling, which leverages RNA data and machine learning to combine biological signals, creating multidimensional biomarkers for new diagnostics to improve patient outcomes.

N
Novx

NOVX Systems is a medical device company that is combing expertise in photonics, engineering, polymer chemistry, physics, molecular biology and data management, to create solutions for office-based patient testing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.